Oxford Immunotec Global PLC (NASDAQ:OXFD) shares traded down 4.2% on Monday . The stock traded as low as $7.89 and last traded at $7.90, with a volume of 53,487 shares trading hands. The stock had previously closed at $8.25.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Oxford Immunotec Global PLC in a research note on Monday, June 27th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Sunday, June 26th.

The firm’s 50 day moving average price is $8.87 and its 200-day moving average price is $9.85. The firm’s market cap is $178.27 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). The firm earned $17.10 million during the quarter, compared to the consensus estimate of $16.96 million. The business’s revenue was up 23.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) EPS. Analysts anticipate that Oxford Immunotec Global PLC will post ($1.28) EPS for the current year.

A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. raised its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned about 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent quarter.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.